Multicenter randomized trial demonstrates anti-CD49d reduces infarct size only in small cortical strokes in mice, indicating neuroprotection depends on lesion severity.
Key Points
To confirm the preclinical efficacy of anti-CD49d antibodies in acute brain ischemia and establish the feasibility of conducting a preclinical randomized controlled multicenter trial.
Centrally coordinated, randomized, and blinded preclinical trial conducted across six independent European research centers.
Tested anti-CD49d antibodies in two distinct mouse models: permanent distal middle cerebral artery occlusion and transient proximal middle cerebral artery occlusion.
Anti-CD49d antibody therapy significantly reduced both leukocyte invasion and infarct volume following permanent distal middle cerebral artery occlusion causing small cortical infarctions.
Anti-CD49d treatment did not significantly decrease lesion size or alter leukocyte invasion following transient proximal middle cerebral artery occlusion inducing large ischemic lesions.